Loading
A phase 2 trial of Bevacizumab, Lenvatinib, Rilvegostomig in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer is a phase 2 interventional study registered as NCT05775159 by AstraZeneca, with 294 participants planned, started 2023-04-24 and due to reach its primary completion in 2026-10-27. Interventions recorded: Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine. Conditions listed: Hepatocellular Carcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
Shares Rilvegostomig, AstraZeneca.
Shares Rilvegostomig, Gemcitabine, AstraZeneca, Cisplatin.
Shares Rilvegostomig, AstraZeneca, Cisplatin.
Shares Rilvegostomig, AstraZeneca, Cisplatin.
Shares Rilvegostomig, AstraZeneca.
Shares Rilvegostomig, AstraZeneca.
Shares Rilvegostomig, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/